Elevated dopamine turnover in the putamen was suggested to be an even more sensitive subclinical indicator of PD in LRRK2 mutation carriers compared with reduced dopaminergic terminal integrity as assessed by VMAT2 and DAT binding (218). This evidence concerns the gene SLC18A2 and Parkinson disease.